Cardiogen 20 mg

Cardiogen is a short peptide bioregulator developed within the Khavinson school of peptide research at the Saint Petersburg Institute of Bioregulation and Gerontology. Classified as a synthetic tripeptide with the sequence Ala-Glu-Asp (AED), Cardiogen was developed to investigate how minimal peptide sequences interact with cardiac tissue and cardiovascular research models. Its compact structure positions Cardiogen as a useful research compound for studying tissue-specific peptide signaling in laboratory contexts.

At the cellular and molecular level, Cardiogen is studied for its proposed ability to engage with chromatin structure and modulate transcriptional activity within cardiomyocyte and cardiac fibroblast cell models. Research observations within the Khavinson framework suggest that short bioregulator peptides interact with specific DNA regions to influence the expression of genes associated with cardiomyocyte maintenance, extracellular matrix synthesis, and cardiac-tissue stress adaptation. These observations are consistent with the broader proposition that short peptides act as gene-expression regulators within tissues from which their parent peptide complexes were originally extracted.

Research interest in Cardiogen centers on cardiac-tissue gene expression studies, cardiomyocyte research models, and cardiovascular fibroblast investigations. Comparative work on tissue-specific bioregulators positions Cardiogen alongside other cardiac-targeted oligopeptides used to explore peptidergic regulation of cardiovascular biology in cell-culture and animal research models (Khavinson V.K., Anisimov V.N., 2009, Advances in Gerontology). Additional reports within the Khavinson tradition describe how the AED sequence influences gene-expression activation in cardiac research models, supporting continued laboratory investigation of Cardiogen in cardiac and cardiovascular biology research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

The development of short peptide bioregulators began in the 1970s at the Military Medical Academy in Saint Petersburg, where Professor Vladimir Khavinson and colleagues isolated peptide fractions from animal tissues that appeared to restore organ-specific function in experimental models. This work led to the founding of the Saint Petersburg Institute of Bioregulation and Gerontology and the systematic study of tissue-derived peptide complexes, including the cardiac peptide complex from which Cardiogen was later derived.

Cardiogen was identified within this research program as a synthetic tripeptide bioregulator with the sequence Ala-Glu-Asp (AED), associated with cardiac tissue and cardiovascular research models. Subsequent biochemical and molecular investigations explored how this peptide interacts with chromatin and influences gene-expression patterns in cardiomyocyte and cardiac fibroblast cell systems, supporting the hypothesis that minimal peptide sequences can act as tissue-specific gene-expression modulators within cardiac and cardiovascular cell models.

Today, Cardiogen is positioned within the wider family of Khavinson-school oligopeptides studied for cardiac-tissue gene expression, cardiomyocyte research, and cardiovascular fibroblast research in laboratory contexts.

1. Chromatin Interaction and Gene-Expression Modulation

Within the Khavinson framework, Cardiogen is proposed to interact with specific regions of double-stranded DNA and associated chromatin proteins, where it has been reported to influence gene-expression activation in cardiomyocyte and cardiac fibroblast research models. This proposed mode of action positions Cardiogen as a tool for investigating peptide-mediated chromatin remodeling and transcriptional regulation in cardiac tissues.

2. Cardiomyocyte Signaling and Cardiac-Tissue Pathways

Research observations suggest that Cardiogen engages with intracellular signaling pathways relevant to cardiomyocyte function, including pathways associated with cardiac stress-response gene expression research and cardiomyocyte maintenance research models. These observations make Cardiogen a useful compound for exploring tissue-specific peptide signaling in cardiac cell-culture systems.

3. Cardiac Fibroblast and Extracellular Matrix Research

Comparative work on short peptide bioregulators indicates that the AED sequence is associated with gene-expression and matrix-protein synthesis changes in cardiac fibroblast cell models, including studies of aged cardiac tissue populations. In cardiac fibroblast research models, Cardiogen is investigated for its role in collagen and elastin expression studies, extracellular matrix remodeling research, and age-related cardiac chromatin organization investigations.

4. Adaptive and Homeostatic Signaling

Khavinson-school bioregulators are described as adaptive peptide regulators that operate under physiological stress conditions. Cardiogen is studied for its proposed contribution to cardiac-tissue homeostasis research, including models of age-related decline in cardiomyocyte signaling and oxidative stress adaptation.

Research Applications

Conclusion

Cardiogen is a Khavinson-school short peptide bioregulator with the sequence Ala-Glu-Asp, studied for its proposed role in cardiac-tissue gene expression, cardiomyocyte research, and cardiac fibroblast research. Its compact tripeptide structure and dual cardiomyocyte-fibroblast positioning make Cardiogen a valuable laboratory compound for exploring peptidergic regulation of gene expression in research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.